tiprankstipranks
Trending News
More News >
Resonance Health Ltd (AU:RHT)
ASX:RHT
Australian Market

Resonance Health Ltd (RHT) AI Stock Analysis

Compare
2 Followers

Top Page

AU

Resonance Health Ltd

(Sydney:RHT)

Rating:64Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
Resonance Health Ltd shows a solid financial foundation driven by strong revenue growth and improved cash flow, which are significant strengths. However, technical analysis indicates mixed signals with some resistance and limited upward momentum. Valuation concerns due to a negative P/E ratio and lack of dividend yield weigh down the overall score.

Resonance Health Ltd (RHT) vs. iShares MSCI Australia ETF (EWA)

Resonance Health Ltd Business Overview & Revenue Model

Company DescriptionResonance Health Limited, a healthcare technology and services company, designs, develops, and manufactures software-as-medical devices in the Asia Pacific, North America, South America, Europe, the Middle East, and Africa. It offers FerriScan, a non-invasive MRI based system for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) assisted device for the automated real-time assessment of LIC; HepaFat-AI, an AI-assisted device for the automated real-time multi-metric measurement of liver-fat; CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading; HepaFat-Scan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; and LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFat-AI into a consolidated report. It also offers quantitative imaging measurements and CRO, such as quality-assured image analysis, imaging charter development, project and data management, issue resolution, site tracker and clinical trial progress report, and coordination of data flow services; biomarkers, blood, urine, and protein analytes, as well as RNA, DNA, and genotyping services; and protocol development, assessment of subject inclusion or exclusion, decisions on dose modifications, and evaluating the safety profile of a new therapy, as well as supporting primary and secondary end-points demonstrating drug efficacy services for multinational and multicenter clinical trials; and phantoms for the calibration of MRI machines. The company serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.
How the Company Makes MoneyResonance Health Ltd generates revenue through the sale and licensing of its proprietary medical imaging software products, such as FerriScan, to healthcare providers and diagnostic imaging centers. The company's revenue model is based on charging fees for the use of its diagnostic services, which include image analysis and reporting. Additionally, Resonance Health may engage in partnership agreements with healthcare institutions and research organizations to expand the reach and application of its technologies. These collaborations can also contribute to the company's earnings through joint ventures or co-development projects.

Resonance Health Ltd Financial Statement Overview

Summary
Resonance Health Ltd demonstrates strong revenue growth and a return to profitability, with a robust balance sheet and improved cash flow generation. However, the negative EBITDA margin highlights some operational challenges.
Income Statement
82
Very Positive
Resonance Health Ltd has shown strong revenue growth of 95% year-over-year, indicating robust demand for its services. The gross profit margin remains high at 100%, reflecting efficient cost management. The company has turned around its profitability, achieving a net profit margin of 1.97% compared to a loss in the previous year. However, the negative EBITDA margin indicates some underlying operational challenges that need attention.
Balance Sheet
76
Positive
The company maintains a healthy equity ratio of 53.9%, suggesting financial stability and a strong capital base. A low debt-to-equity ratio of 0.34 indicates conservative leverage, which reduces financial risk. Return on equity is modest at 1.55%, reflecting room for improvement in generating returns for shareholders.
Cash Flow
88
Very Positive
Operating cash flow has improved significantly, turning positive and resulting in a substantial free cash flow growth rate. The free cash flow to net income ratio is strong, indicating that the company efficiently converts its profits into cash. The operating cash flow to net income ratio is also healthy, showing effective cash management.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue10.53M8.59M4.40M3.83M3.78M3.67M
Gross Profit10.53M8.59M4.40M3.83M3.78M3.67M
EBITDA-1.14M-382.00K-1.19M-1.34M552.35K-839.00K
Net Income-309.14K169.30K-780.00K-1.14M585.86K-715.00K
Balance Sheet
Total Assets17.94M20.28M10.98M11.69M12.44M10.50M
Cash, Cash Equivalents and Short-Term Investments3.51M6.85M6.36M6.78M8.86M6.97M
Total Debt3.60M3.70M272.94K268.22K60.10K116.10K
Total Liabilities7.90M9.35M1.05M995.58K611.74K591.04K
Stockholders Equity10.04M10.93M9.94M10.69M11.83M9.91M
Cash Flow
Free Cash Flow2.41M1.01M-624.93K-1.42M772.72K1.06M
Operating Cash Flow2.53M1.39M-157.03K-712.67K1.17M1.31M
Investing Cash Flow-7.77M-3.94M-467.90K-704.00K-395.79K-250.63K
Financing Cash Flow2.78M3.01M-81.97K-107.11K1.20M2.82M

Resonance Health Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.04
Price Trends
50DMA
0.04
Positive
100DMA
0.04
Negative
200DMA
0.05
Negative
Market Momentum
MACD
<0.01
Negative
RSI
51.70
Neutral
STOCH
22.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RHT, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.70 is Neutral, neither overbought nor oversold. The STOCH value of 22.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:RHT.

Resonance Health Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AURHT
64
Neutral
AU$19.76M140.00-3.11%89.13%69.57%
AUPCK
55
Neutral
AU$66.31M-457.46%21.93%10.34%
AUSHG
54
Neutral
AU$107.10M
52
Neutral
kr5.55B11.43-72.81%7.82%28.10%22.23%
AUIME
46
Neutral
AU$15.29M-17.24%34.47%41.83%
AUEMD
44
Neutral
AU$16.51M-74.80%-9.16%89.23%
AUHIQ
39
Underperform
AU$6.90M
18.53%33.17%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%
AU:SHG
Singular Health Group Ltd
0.36
0.26
260.00%
AU:IME
ImExHS Limited
0.26
-0.22
-45.83%
AU:EMD
Emyria Ltd
0.03
-0.02
-40.00%
AU:HIQ
HitIQ Limited
0.01
-0.01
-50.00%
AU:PCK
PainChek Ltd
0.04
0.01
33.33%

Resonance Health Ltd Corporate Events

Resonance Health Expands TrialsWest with New Mandurah Site
Jul 8, 2025

Resonance Health Ltd is expanding its TrialsWest business with the opening of a third clinical trial site in Mandurah, Western Australia, expected in August 2025. This expansion is part of the company’s strategy to increase participant capacity and enhance its clinical trial operations, particularly for major pharmaceutical trials. The new site in Mandurah, a rapidly growing city, aligns with the company’s goal to establish trial sites in accessible, densely populated areas with low setup costs, supporting its long-term growth and market positioning.

Resonance Health Director Increases Shareholding
Jun 27, 2025

Resonance Health Ltd has announced a change in the director’s interest, with Simon Panton acquiring an additional 500,000 ordinary fully paid shares through an on-market trade. This acquisition, valued at $17,500, increases Panton’s total shareholding to 74,800,000 shares, reflecting a strategic move that could influence the company’s governance and shareholder dynamics.

Resonance Health Launches InvestorHub to Enhance Investor Engagement
Jun 10, 2025

Resonance Health Ltd has launched ‘InvestorHub’, a new platform aimed at enhancing engagement with investors and market participants. This initiative is part of the company’s strategy to support its growth across three business areas: Clinical Trial Management, SaMD Image Analysis Services, and Clinical Trial Site Services. The InvestorHub will provide a centralized location for shareholders to access company announcements and updates, fostering better communication and interaction with the company’s leadership. This move is expected to support Resonance Health’s ongoing expansion and innovation efforts, as it continues to scale its operations and strengthen its market position.

Resonance Health Reports Record Cash Receipts and Strategic Growth Initiatives
Apr 29, 2025

Resonance Health Ltd reported record cash receipts of $14.9M over the last 12 months, with a positive cash flow from operations. The company completed a cost efficiency program, resulting in significant annual savings, and is progressing with major clinical trials and contract extensions in its SaMD business. The TrialsWest division is set for strong growth with new contracts and expanded capacity. The company is enhancing automation and efficiency to serve more customers at a lower cost, expecting annual savings of approximately $1.1M.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 02, 2025